Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Patients With Glioblastoma Multiforme (GBM)

NCT02386826 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT02386826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02386826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Patients With Glioblastoma Multiforme (GBM)
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 1
Overall status
Completed
Start date
September 22, 2015
Completion date
August 23, 2023
Enrollment
65 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, glioblastoma multiforme, gliosarcoma, renal cell carcinoma